Screener / SEC EDGAR /CIK 0001114483 /10-K filed Feb 23, 2026, compared with Feb 20, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
NYSE Health care · Medical Devices

Integer Holdings Corp ITGR

Integer Holdings Corporation, headquartered in Plano, Texas, is one of the world’s largest medical device contract development and manufacturing organizations (“CDMOs”), serving the Cardio and Vascular, Neuromodulation, and Cardiac Rhythm Management markets. 10-K, Item 1

Employees
11,000
Headquarters
Plano, TX
CEO
Payman Khales
Next results
around Feb 18, 2027
Compare with peers Embed

Where each dollar of revenue went, FY2025

Revenue of $1.9B through the costs to a net profit of $102.8M · income statement of the 10-K

12% operating margin
Revenue to Gross profit: $500.4MRevenue to Cost of revenue: $1.4BGross profit to Operating profit: $221.3MGross profit to Operating expenses: $279.1MOperating profit to Net profit: $102.8MOperating profit to Tax & other: $118.5MOperating expenses to R&D: $49.5MOperating expenses to Sales, admin & other: $229.6M Revenue: $1.9B REVENUE $1.9B +8% Y/Y Gross profit: $500.4M · 27% margin GROSS PROFIT $500.4M 27% margin · +9% Y/Y Cost of revenue: $1.4B · 73% of revenue COST OF REVENUE $1.4B 73% of revenue Operating profit: $221.3M · 12% margin OPERATING PROFIT $221.3M 12% margin · +6% Y/Y Operating expenses: $279.1M · 15% of revenue OPERATING EXPENSES $279.1M 15% of revenue Net profit: $102.8M · 6% margin NET PROFIT $102.8M 6% margin · −14% Y/Y Tax & other: $118.5M · 6% of revenue TAX & OTHER $118.5M 6% of revenue R&D: $49.5M · 3% of revenue R&D $49.5M 3% of revenue Sales, admin & other: $229.6M · 12% of revenue SALES, ADMIN & OTHER $229.6M 12% of revenue
Gross profit $500.4M 27% margin · +9% Y/Y
Operating profit $221.3M 12% margin · +6% Y/Y
Net profit $102.8M 6% margin · −14% Y/Y
The full income statement, year by year

ITGR among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.

Compare
Revenue growth: 8.0%, above 40% of 154 peers (their median 10.5%) REVENUE GROWTH 8.0% · above 40% Gross margin: 24.6%, above 7% of 107 peers (their median 63.8%) GROSS MARGIN 24.6% · above 7% Operating margin: 8.2%, above 45% of 138 peers (their median 10.2%) OPERATING MARGIN 8.2% · above 45% Net margin: 5.7%, above 48% of 153 peers (their median 6.8%) NET MARGIN 5.7% · above 48% FCF margin: 4.5%, above 32% of 144 peers (their median 10.1%) FCF MARGIN 4.5% · above 32% Return on capital: 6.2%, above 26% of 89 peers (their median 9.2%) RETURN ON CAPITAL 6.2% · above 26%
ITGR Peer median Below the median

What changed

22 new risk paragraphs and 2 accounting facts worth reading about. 10-K filed Feb 23, 2026 against Feb 20, 2025.

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

2facts worth reading about the other 9 checks found nothing to note

  • Receivables growing faster than revenue
    Receivables +41.1% ($245.3M to $346.1M) vs revenue +8.0% ($1.7B to $1.9B), +33.1 pts apart
  • Critical audit matters changed
    New this year: Inventories - Excess and Obsolete Inventory (“Inventories are stated at the lower of cost, determined using the first-in first-out method, or net realizable value. The valuation of inventory requires the Company to estimate obsolete or excess inventory, as well as inventory that is not of saleable quality. Variations in assumptions used could h”); Debt - Induced Conversion of Convertible Debt Instrument (“On March 18, 2025, the Company issued 2030 Convertible Notes and concurrently utilized a portion of the proceeds to exchange an amount of 2028 Convertible Notes for cash and shares of Common Stock (the “Note Exchange Transactions”). The Company determined that the Note Exchange Transactions met the ”). No longer listed: Inventories
  • Cash from operations $196.1M vs net income $102.8M (FY ending Dec 31, 2025)
8 more checks with nothing to note
  • Inventory +2.7% ($247.1M to $253.7M) vs revenue +8.0% ($1.7B to $1.9B), -5.3 pts apart
  • Same auditor in both 10-Ks: Deloitte & Touche LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

22 paragraphs in Risk Factors that were not in the 10-K filed Feb 20, 2025. Quoted as filed.

All 22 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 20, 2025 10-K, ITEM 1A
    Many of our products have a long production cycle, and we must anticipate demand for our products to ensure adequate manufacturing and testing capacity and make certain decisions based on our estimates, including determining the levels of business that we will seek and accept, production schedules, component procurement commitments,…
  2. Item 1A · new paragraph · not in the 10-K filed Feb 20, 2025 10-K, ITEM 1A
    Heightened geopolitical tensions and resulting trade restrictions, including escalating or retaliatory tariffs between regions, could increase the cost of our products or otherwise make products manufactured in certain locations less competitive in key markets, which could reduce customer demand and impair our ability to successfully…
  3. Item 1A · new paragraph · not in the 10-K filed Feb 20, 2025 10-K, ITEM 1A
    In addition, some of our competitors outside of the U.S. may have resources and support from their governments that we do not, such as preferences for local manufacturers, and may not be subject to the same tariffs, trade policies, trade compliance regulations and government investigations as us. Our competitors are not all subject to…
  4. Item 1A · new paragraph · not in the 10-K filed Feb 20, 2025 10-K, ITEM 1A
    The price of our common stock has been and is likely to continue to be volatile. For example, between January 1, 2025 and February 18, 2026, our common stock’s daily closing price on NYSE has ranged from a low of $63.32 to a high of $144.36. Some companies that have experienced volatility in the trading price of their stock have been…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$1.3B$1.6B$1.7B$1.9B
Net income$66.4M$90.7M$119.9M$102.8M
Operating cash flow$116.4M$180.2M$205.2M$196.1M
Free cash flow$41.7M$60.3M$99.8M$105.1M

Revenue, FY2016 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$1.9B ▲ 8.0% in FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

3 filings in the last 30 days · SEC EDGAR

All filings

About the company

Integer Holdings Corp, Plano, TX · from the 10-K filed Feb 23, 2026

Integer Holdings Corporation, headquartered in Plano, Texas, is one of the world’s largest medical device contract development and manufacturing organizations (“CDMOs”), serving the Cardio and Vascular, Neuromodulation, and Cardiac Rhythm Management markets. As a strategic partner of choice, we advance the goals of our medical device customers through industry-leading engineering and manufacturing, with a relentless commitment to quality, service, and innovation. Our brands include Greatbatch Medical® and Lake Region Medical®. Our primary customers include large, multi-national original equipment manufacturers (“OEMs”) and their affiliated subsidiaries.

Headquarters
Plano, TX
Country
United States
Reports in
USD
Listed on
NYSE
Fiscal year ends
December 31
Last results
Oct 29, 2026
Incorporated in
DE

Employees, at the top of the page: "As of December 31, 2025, Integer employed approximately 11,000 associates in addition to a contingent workforce of approximately 400 to assist with various projects and service functions and address peaks in staff requirements" (10-K). Address and exchange: SEC's company file.

Email alerts

Sources

The 10-K filed Feb 23, 2026 (open at SEC), compared with the 10-K filed Feb 20, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ITGR/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.